nach oben

International Journal of Clinical Oncology

Erschienen in:

01.04.2015 | Original Article

Combination of MUC1 and MUC4 expression predicts clinical outcome in patients with oral squamous cell carcinoma

verfasst von: Yoshiaki Kamikawa, Yuji Kanmura, Tomofumi Hamada, Norishige Yamada, Muzafar A. Macha, Surinder K. Batra, Michiyo Higashi, Suguru Yonezawa, Kazumasa Sugihara

Erschienen in: International Journal of Clinical Oncology | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

Background

Both MUC1 and MUC4 are high molecular weight glycoproteins and are independent indicators of worse prognosis in many human epithelial cancers including oral squamous cell carcinoma (OSCC). However, there has been no investigation of the clinical importance of the co-expression of MUC1 and MUC4 in OSCC. The aim of this study was to evaluate the co-expression profile of MUC1/MUC4 and analyze the prognostic significance in OSCC.

Methods

We examined the expression profile of MUC1 and MUC4 in OSCC tissues from 206 patients using immunohistochemistry. The co-expression profile of MUC1/MUC4 and its prognostic significance in OSCC was statistically analyzed.

Results

MUC1 and MUC4 overexpression were strongly correlated with each other (p < 0.0001) and a combination of both MUC1 and MUC4 expression was a powerful indicator for tumor aggressiveness such as tumor size (p = 0.014), lymph node metastasis (0.0001), tumor stage (p = 0.006), diffuse invasion (p = 0.028), and vascular invasion (p = 0.014). The MUC1/MUC4 double-positive patients showed the poorest overall and disease-free survival. Multivariate analysis revealed that MUC1/MUC4 double-positivity was the strong independent prognostic factor for overall and disease-free survival (p = 0.007 and (p = 0.0019), in addition to regional recurrence (p = 0.0025).

Conclusions

Taken together, these observations indicate that the use of a combination of MUC1/MUC4 can predict outcomes for patients with OSCC. This combination is also a useful marker for predicting regional recurrence. MUC1 and MUC4 may be attractive targets for the selection of treatment methods in OSCC.

Nur mit Berechtigung zugänglich

Jemal A, Bray F, Center MM et al (2011) Global cancer statistics. CA Cancer J Clin 61:69–90CrossRefPubMed

Warnakulasuriya S (2009) Global epidemiology of oral and oropharyngeal cancer. Oral Oncol 45:309–316CrossRefPubMed

Cheng A, Schmidt BL (2008) Management of the N0 neck in oral squamous cell carcinoma. Oral Maxillofac Surg Clin N Am 20:477–497CrossRef

Kowalski LP, Bagietto R, Lara JR et al (2000) Prognostic significance of the distribution of neck node metastasis from oral carcinoma. Head Neck 22:207–214CrossRefPubMed

Capote A, Escorial V, Munoz-Guerra MF et al (2007) Elective neck dissection in early-stage oral squamous cell carcinoma—does it influence recurrence and survival? Head Neck 29:3–11CrossRefPubMed

Mahfouz ME, Rodrigo JP, Takes RP et al (2010) Current potential and limitations of molecular diagnostic methods in head and neck cancer. Eur Arch Otorhinolaryngol 267:851–860CrossRefPubMed

Hollingsworth MA, Swanson BJ (2004) Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer 4:45–60CrossRefPubMed

Moniaux N, Escande F, Porchet N et al (2001) Structural organization and classification of the human mucin genes. Front Biosci 6:1192–1206CrossRef

Kufe DW (2009) Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer 9:874–885CrossRefPubMedCentralPubMed

10.

Shibahara H, Tamada S, Higashi M et al (2004) MUC4 is a novel prognostic factor of intrahepatic cholangiocarcinoma-mass forming type. Hepatology 39:220–229CrossRefPubMed

11.

Higashi M, Yonezawa S, Ho JJ et al (1999) Expression of MUC1 and MUC2 mucin antigens in intrahepatic bile duct tumors: its relationship with a new morphological classification of cholangiocarcinoma. Hepatology 30:1347–1355CrossRefPubMed

12.

Nakamura A, Horinouchi M, Goto M et al (2002) New classification of pancreatic intraductal papillary-mucinous tumour by mucin expression: its relationship with potential for malignancy. J Pathol 197:201–210CrossRefPubMed

13.

Kitazono I, Higashi M, Kitamoto S et al (2013) Expression of MUC4 mucin is observed mainly in the intestinal type of intraductal papillary mucinous neoplasm of the pancreas. Pancreas 42:1120–1128CrossRefPubMedCentralPubMed

14.

Osako M, Yonezawa S, Siddiki B et al (1993) Immunohistochemical study of mucin carbohydrates and core proteins in human pancreatic tumors. Cancer 71:2191–2199CrossRefPubMed

15.

Sagara M, Yonezawa S, Nagata K et al (1999) Expression of mucin 1 (MUC1) in esophageal squamous-cell carcinoma: its relationship with prognosis. Int J Cancer 84:251–257CrossRefPubMed

16.

Takao S, Uchikura K, Yonezawa S et al (1999) Mucin core protein expression in extrahepatic bile duct carcinoma is associated with metastases to the liver and poor prognosis. Cancer 86:1966–1975CrossRefPubMed

17.

Saitou M, Goto M, Horinouchi M et al (2005) MUC4 expression is a novel prognostic factor in patients with invasive ductal carcinoma of the pancreas. J Clin Pathol 58:845–852CrossRefPubMedCentralPubMed

18.

Shibahara H, Tamada S, Goto M et al (2004) Pathologic features of mucin-producing bile duct tumors: two histopathologic categories as counterparts of pancreatic intraductal papillary-mucinous neoplasms. Am J Surg Pathol 28:327–338CrossRefPubMed

19.

Tamada S, Goto M, Nomoto M et al (2002) Expression of MUC1 and MUC2 mucins in extrahepatic bile duct carcinomas: its relationship with tumor progression and prognosis. Pathol Int 52:713–723CrossRefPubMed

20.

Tamada S, Shibahara H, Higashi M et al (2006) MUC4 is a novel prognostic factor of extrahepatic bile duct carcinoma. Clin Cancer Res 12:4257–4264CrossRefPubMed

21.

Tamura Y, Higashi M, Kitamoto S et al (2012) MUC4 and MUC1 expression in adenocarcinoma of the stomach correlates with vessel invasion and lymph node metastasis: an immunohistochemical study of early gastric cancer. PLoS One 7:e49251CrossRefPubMedCentralPubMed

22.

Tsutsumida H, Goto M, Kitajima S et al (2007) MUC4 expression correlates with poor prognosis in small-sized lung adenocarcinoma. Lung Cancer 55:195–203CrossRefPubMed

23.

Yonezawa S, Goto M, Yamada N et al (2008) Expression profiles of MUC1, MUC2, and MUC4 mucins in human neoplasms and their relationship with biological behavior. Proteomics 8:3329–3341CrossRefPubMed

24.

Yonezawa S, Higashi M, Yamada N et al (2010) Significance of mucin expression in pancreatobiliary neoplasms. J Hepatobiliary Pancreat Sci 17:108–124CrossRefPubMed

25.

Yonezawa S, Higashi M, Yamada N et al (2008) Precursor lesions of pancreatic cancer. Gut Liver 2:137–154CrossRefPubMedCentralPubMed

26.

Yonezawa S, Taira M, Osako M et al (1998) MUC-1 mucin expression in invasive areas of intraductal papillary mucinous tumors of the pancreas. Pathol Int 48:319–322CrossRefPubMed

27.

Yonezawa S, Higashi M, Yamada N et al (2011) Mucins in human neoplasms: clinical pathology, gene expression and diagnostic application. Pathol Int 61:697–716CrossRefPubMed

28.

Yonezawa S, Sato E (1997) Expression of mucin antigens in human cancers and its relationship with malignancy potential. Pathol Int 47:813–830CrossRefPubMed

29.

Yonezawa S, Nakamura A, Horinouchi M et al (2002) The expression of several types of mucin is related to the biological behavior of pancreatic neoplasms. J Hepatobiliary Pancreat Surg 9:328–341CrossRefPubMed

30.

Hamada T, Nomura M, Kamikawa Y et al (2012) DF3 epitope expression on MUC1 mucin is associated with tumor aggressiveness, subsequent lymph node metastasis, and poor prognosis in patients with oral squamous cell carcinoma. Cancer 118:5251–5264CrossRefPubMed

31.

Hamada T, Wakamatsu T, Miyahara M et al (2012) MUC4: a novel prognostic factor of oral squamous cell carcinoma. Int J Cancer 130:1768–1776CrossRefPubMed

32.

Lee HK, Cho MS, Kim TH (2012) Prognostic significance of muc4 expression in gallbladder carcinoma. World J Surg Oncol 10:224CrossRefPubMedCentralPubMed

33.

Sobin LGM, Wittekind Ce (2009) TNM Classification of malignant tumors. In: Hoboken NJ (ed), 7th ed John Wiley & Sons, Inc.

34.

Yamamoto E, Kohama G, Sunakawa H et al (1983) Mode of invasion, bleomycin sensitivity, and clinical course in squamous cell carcinoma of the oral cavity. Cancer 51:2175–2180CrossRefPubMed

35.

Hayes DF, Sekine H, Ohno T et al (1985) Use of a murine monoclonal antibody for detection of circulating plasma DF3 antigen levels in breast cancer patients. J Clin Invest 75:1671–1678CrossRefPubMedCentralPubMed

36.

Nagy P, Friedländer E, Tanner M et al (2005) Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a Herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res 65:473–482PubMed

37.

Singh AP, Chaturvedi P, Batra SK (2007) Emerging roles of MUC4 in cancer: a novel target for diagnosis and therapy. Cancer Res 67:433–436CrossRefPubMed

38.

Yamada N, Nishida Y, Tsutsumida H et al (2008) MUC1 expression is regulated by DNA methylation and histone H3 lysine 9 modification in cancer cells. Cancer Res 68:2708–2716CrossRefPubMed

39.

Yamada N, Nishida Y, Tsutsumida H et al (2009) Promoter CpG methylation in cancer cells contributes to the regulation of MUC4. Br J Cancer 100:344–351CrossRefPubMedCentralPubMed

40.

Vincent A, Ducourouble MP, Van Seuningen I (2008) Epigenetic regulation of the human mucin gene MUC4 in epithelial cancer cell lines involves both DNA methylation and histone modifications mediated by DNA methyltransferases and histone deacetylases. FASEB J 22:3035–3045CrossRefPubMed

41.

Zhang L, Vlad A, Milcarek C et al (2013) Human mucin MUC1 RNA undergoes different types of alternative splicing resulting in multiple isoforms. Cancer Immunol Immunother 62:423–435CrossRefPubMedCentralPubMed

42.

Obermair A, Schmid BC, Packer LM et al (2002) Expression of MUC1 splice variants in benign and malignant ovarian tumours. Int J Cancer 100:166–171CrossRefPubMed

43.

Schmid BC, Rudas M, Fabjani G et al (2003) Evaluation of MUC1 splice variants as prognostic markers in patients with ductal carcinoma in situ of the breast. Oncol Rep 10:1981–1985PubMed

44.

Choudhury A, Moniaux N, Winpenny JP et al (2000) Human MUC4 mucin cDNA and its variants in pancreatic carcinoma. J Biochem 128:233–243CrossRefPubMed

45.

Moniaux N, Escande F, Batra SK et al (2000) Alternative splicing generates a family of putative secreted and membrane-associated MUC4 mucins. Eur J Biochem 267:4536–4544CrossRefPubMed

46.

Choudhury A, Moniaux N, Ringel J et al (2001) Alternate splicing at the 30-end of the human pancreatic tumor-associated mucin MUC4 cDNA. Teratog Carcinog Mutagen 21:83–96CrossRefPubMed

Titel: Combination of MUC1 and MUC4 expression predicts clinical outcome in patients with oral squamous cell carcinoma
verfasst von: Yoshiaki Kamikawa
Yuji Kanmura
Tomofumi Hamada
Norishige Yamada
Muzafar A. Macha
Surinder K. Batra
Michiyo Higashi
Suguru Yonezawa
Kazumasa Sugihara
Publikationsdatum: 01.04.2015
Verlag: Springer Japan
Erschienen in: International Journal of Clinical Oncology / Ausgabe 2/2015
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-014-0710-6

Neu im Fachgebiet Onkologie

22.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Combination of MUC1 and MUC4 expression predicts clinical outcome in patients with oral squamous cell carcinoma

Abstract

Background

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

AML: Komplettremission kein Muss für erfolgreiche Stammzelltransplantation

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Background

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2015

The present state and perception of young women with breast cancer towards breast reconstructive surgery

Hyponatremia as a powerful prognostic predictor for Japanese patients with clear cell renal cell carcinoma treated with a tyrosine kinase inhibitor

[18F]fluoro-2-deoxyglucose-positron emission tomography for the assessment of histopathological response after preoperative chemoradiotherapy in advanced oral squamous cell carcinoma

Mechanisms of hormonal therapy resistance in breast cancer

Expression of costimulatory molecules B7-H1, B7-H4 and Foxp3+ Tregs in gastric cancer and its clinical significance

Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer

Neu im Fachgebiet Onkologie

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

AML: Komplettremission kein Muss für erfolgreiche Stammzelltransplantation

Update Onkologie